CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.97B, above the global median of $1.2B
- PositionPrice-to-book is 1.29×, lower than 95% of its Biotechnology peers (median 4.7×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.97BUSDvs all stocks (USD)
Revenue (TTM)
1.97BUSDvs all stocks (USD)
Profit Margin
-6.93%vs Biotechnology peers
Beta
0.2610xvs all stocks
52-Week Change
-1.59%vs all stocks
Market Capitalization
1.97BUSDvs all stocks (USD)
Enterprise Value
2.25BUSDvs all stocks (USD)
Forward P/E
7.09xvs Biotechnology peers
Price to Sales (TTM)
0.9988xvs Biotechnology peers
Price to Book (MRQ)
1.29xvs Biotechnology peers
Enterprise to Revenue
1.14xvs Biotechnology peers
Enterprise to EBITDA
-128.10xvs Biotechnology peers
Gross Margin
62.77%vs Biotechnology peers
Profit Margin
-6.93%vs Biotechnology peers
Operating Margin
13.03%vs Biotechnology peers
Return on Assets (TTM)
-1.13%vs Biotechnology peers
Return on Equity (TTM)
-9.48%vs Biotechnology peers
Revenue (TTM)
1.97BUSDvs all stocks (USD)
Revenue per Share (TTM)
19.00USDUpdated Sep 28, 2026Quarterly Revenue Growth
-34.30%vs Biotechnology peers
Gross Profit (TTM)
377.26MUSDvs all stocks (USD)
EBITDA (TTM)
-17.53MUSDvs all stocks (USD)
Net Income (TTM)
-136.72MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-34.34%vs Biotechnology peers
Operating Cash Flow (TTM)
111.01MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
22.14MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.20BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
839.61MUSDFY2025 · Dec 31, 2025Gross Profit
1.36BUSDFY2025 · Dec 31, 2025Operating Income
-657.77MUSDvs all stocks (USD)
Pre-tax Income
-702.23MUSDFY2025 · Dec 31, 2025Income Tax Expense
11.19MUSDFY2025 · Dec 31, 2025Net Income
-713.41MUSDFY2025 · Dec 31, 2025EBIT
-664.09MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-578.50MUSDFY2025 · Dec 31, 2025Research & Development
1.52BUSDFY2025 · Dec 31, 2025Selling, General & Administrative
491.72MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
36.69MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
38.14MUSDFY2025 · Dec 31, 2025EPS (Basic)
-7.13USDFY2025 · Dec 31, 2025EPS (Diluted)
-7.13USDFY2025 · Dec 31, 2025Basic Shares Outstanding
100.12MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
100.12MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-713.41MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-475.71MUSDFY2025 · Dec 31, 2025Free Cash Flow
-577.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
814.41MUSDFY2025 · Dec 31, 2025Income Tax Paid
37.63MUSDFY2025 · Dec 31, 2025Interest Paid
14.91MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-713.41MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
44.52MUSDFY2025 · Dec 31, 2025Stock-based Compensation
123.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
70.59MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
203.75MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
104.27MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-308.83MUSDFY2025 · Dec 31, 2025Capital Expenditures
-101.97MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-7.88MUSDFY2025 · Dec 31, 2025Net Acquisitions
174.09MUSDFY2025 · Dec 31, 2025Purchase of Investments
-290.48MUSDFY2025 · Dec 31, 2025Sale of Investments
295.87MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
77.52MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-162.59MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-25.01MUSDFY2025 · Dec 31, 2025Other Financing Charges
-19.45MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-187.05MUSDFY2025 · Dec 31, 2025Shares Outstanding
105.62MSharesUpdated Sep 28, 2026Float Shares
100.54MSharesUpdated Sep 28, 2026Shares Short
25.43MSharesUpdated Sep 28, 2026Short Ratio
8.24daysvs all stocks
Short % of Shares Outstanding
28.86%vs all stocks
% Held by Insiders
4.88%vs all stocks
% Held by Institutions
103.77%vs all stocks
Total Cash (MRQ)
788.49MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.46USDUpdated Sep 28, 2026Total Debt (MRQ)
1.06BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6954xvs Biotechnology peers
Current Ratio (MRQ)
4.42xvs Biotechnology peers
Book Value per Share (MRQ)
14.46USDUpdated Sep 28, 2026Total Assets
3.35BUSDvs all stocks (USD)
Total Current Assets
2.54BUSDFY2025 · Dec 31, 2025Total Liabilities
2.21BUSDFY2025 · Dec 31, 2025Total Non-current Assets
811.76MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.11BUSDFY2025 · Dec 31, 2025Total Current Liabilities
1.10BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
801.28MUSDFY2025 · Dec 31, 2025Other Short-term Investments
138.37MUSDFY2025 · Dec 31, 2025Accounts Receivable
398.23MUSDFY2025 · Dec 31, 2025Inventory
914.74MUSDFY2025 · Dec 31, 2025Accounts Payable
280.84MUSDFY2025 · Dec 31, 2025Short-term Debt
11.39MUSDFY2025 · Dec 31, 2025Deferred Revenue
443.40MUSDFY2025 · Dec 31, 2025Long-term Debt
1.03BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.53MUSDFY2025 · Dec 31, 2025Common Stock (Book)
11.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-4.88BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.14BUSDvs all stocks (USD)
Treasury Stock
25.26MUSDFY2025 · Dec 31, 202552-Week Low
14.68USDUpdated Sep 28, 202652-Week High
25.32USDUpdated Sep 28, 202652-Week Change
-1.59%vs all stocks
Beta
0.2610xvs all stocks
50-Day MA
18.68USDUpdated Sep 28, 2026200-Day MA
19.21USDUpdated Sep 28, 2026Avg 10-Day Volume
2.86MSharesUpdated Sep 28, 2026Avg 30-Day Volume
3.01MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.57USDUpdated Sep 28, 2026Other Income / Expense
-43.00MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 1.29×, lower than 95% of its Biotechnology peers (median 4.7×)Notable
Price-to-book: 1.29Industry median: 4.70Industry P5: 1.33Peers compared: 184
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.63Profit Margin: -0.07
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 4.42Altman Z-Score: -0.98
Financial Health
Altman Z-Score -0.98: distress zoneCritical
Altman Z-Score: -0.98
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.97B, above the global median of $1.2BNotable
Market cap (USD): 1,972,056,482Global Median: 1,201,862,193
Revenue is $1.97B, above the global median of $558.46MNotable
Revenue (USD): 1,974,343,936Global Median: 558,459,881.051
Levered free cash flow is $22.14M, above the global median of $18.92MNotable
Levered free cash flow (USD): 22,139,876Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Biohaven Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Galapagos NV
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nektar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Agios Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Urogen Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zymeworks Inc.
Tier 1ProductionApproval-Gated PipelineRule
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking